Saxton RA, Knockenhauer KE, Wolfson RL, et al. Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway. Science. 2016;351(6268):53-8. doi:10.1126/science.aad2087
Scolnick EM, Petryshen T, Sklar P. Schizophrenia: do the genetics and neurobiology of neuregulin provide a pathogenesis model?. Harv Rev Psychiatry. 2006;14(2):64-77. doi:10.1080/10673220600642960
Tu D, Zhu Z, Zhou AY, et al. Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep. 2013;3(3):747-58. doi:10.1016/j.celrep.2013.01.033
Shmakov S, Abudayyeh OO, Makarova KS, et al. Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems. Mol Cell. 2015;60(3):385-97. doi:10.1016/j.molcel.2015.10.008
Theriault JR, Felts AS, Bates BS, et al. Discovery of a new molecular probe ML228: an activator of the hypoxia inducible factor (HIF) pathway. Bioorg Med Chem Lett. 2012;22(1):76-81. doi:10.1016/j.bmcl.2011.11.077
Ramkissoon LA, Horowitz PM, Craig JM, et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013;110(20):8188-93. doi:10.1073/pnas.1300252110
Shu S, Lin CY, He HH, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529(7586):413-7. doi:10.1038/nature16508
Dong CK, Urgaonkar S, Cortese JF, et al. Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors. Chem Biol. 2011;18(12):1602-10. doi:10.1016/j.chembiol.2011.09.016
Berger AH, Imielinski M, Duke F, et al. Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene. 2014;33(35):4418-23. doi:10.1038/onc.2013.581
Abudayyeh OO, Gootenberg JS, Konermann S, et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science. 2016;353(6299):aaf5573. doi:10.1126/science.aaf5573